Indication
Metastatic Bladder Small Cell Neuroendocrine Carcinoma
1 clinical trial
3 products
Clinical trial
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Status: Recruiting, Estimated PCD: 2025-02-28
Product
CabozantinibProduct
IpilimumabProduct
Nivolumab